NCT03954600View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 5, 2019

Primary Completion Date

October 2, 2019

Study Completion Date

October 9, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

NPT520-34 (125 mg)

NPT520-34, 125 mg oral capsules (size 1)

DRUG

Placebos (125 mg)

Placebo, 125 mg oral capsules

Trial Locations (1)

85283

Celerion, Inc, Tempe

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Neuropore Therapies Inc.

INDUSTRY

NCT03954600 - A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects | Biotech Hunter | Biotech Hunter